These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 30702581)

  • 1. Efficacy of sorafenib adjuvant therapy in northwestern Chinese patients with non-metastatic renal-cell carcinoma after nephrectomy: A multicenter retrospective study.
    Wei D; Wu G; Zheng Y; Chen F; Lu J; Wang Y; He D; Wang H; Wang Z; Chen P; Wang Y; Wang Z; Ye Y; Zhu Z; Yuan J
    Medicine (Baltimore); 2019 Feb; 98(5):e14237. PubMed ID: 30702581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
    Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
    Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial.
    Eisen T; Frangou E; Oza B; Ritchie AWS; Smith B; Kaplan R; Davis ID; Stockler MR; Albiges L; Escudier B; Larkin J; Bex A; Joniau S; Hancock B; Hermann GG; Bellmunt J; Hodgkinson E; Stewart GD; Barber J; Brown J; McMenemin R; Nathan P; Pickering LM; Parmar MKB; Meade A
    J Clin Oncol; 2020 Dec; 38(34):4064-4075. PubMed ID: 33052759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib.
    Nakano K; Komatsu K; Kubo T; Natsui S; Nukui A; Kurokawa S; Kobayashi M; Morita T
    Jpn J Clin Oncol; 2013 Oct; 43(10):1023-9. PubMed ID: 23956442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between age and sex and mortality after adjuvant therapy for renal cancer.
    Mamtani R; Wang XV; Gyawali B; DiPaola RS; Epperson CN; Haas NB; Dutcher JP
    Cancer; 2019 May; 125(10):1637-1644. PubMed ID: 30620389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis.
    Omae K; Kondo T; Kennoki T; Takagi T; Iizuka J; Kobayashi H; Hashimoto Y; Tanabe K
    Int J Clin Oncol; 2016 Feb; 21(1):126-32. PubMed ID: 26163345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial.
    Ristau BT; Manola J; Haas NB; Heng DYC; Messing EM; Wood CG; Kane CJ; DiPaola RS; Uzzo RG
    J Urol; 2018 Jan; 199(1):53-59. PubMed ID: 28728992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 9. Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial.
    Haas NB; Manola J; Dutcher JP; Flaherty KT; Uzzo RG; Atkins MB; DiPaola RS; Choueiri TK
    JAMA Oncol; 2017 Sep; 3(9):1249-1252. PubMed ID: 28278333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study.
    Zhang H; Dong B; Lu JJ; Yao X; Zhang S; Dai B; Shen Y; Zhu Y; Ye D; Huang Y
    BMC Cancer; 2009 Jul; 9():249. PubMed ID: 19622166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sunitinib versus sorafenib for patients with advanced renal cell carcinoma with renal impairment before the immune-oncology therapy era.
    Takayama T; Kubo T; Yamazaki M; Takeshima S; Komatsubara M; Kameda T; Kamei J; Sugihara T; Fujisaki A; Ando S; Kurokawa S; Fujimura T
    Jpn J Clin Oncol; 2019 Dec; 49(12):1164-1171. PubMed ID: 31665407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma.
    Ikeda M; Fujita T; Mii S; Tanabe K; Tabata K; Matsumoto K; Satoh T; Iwamura M
    Jpn J Clin Oncol; 2012 Sep; 42(9):820-4. PubMed ID: 22782962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Relationship Between the Adverse Events and Efficacy of Sorafenib in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study from Northwest China.
    Zheng Y; Wang F; Wu G; Zhang L; Wang Y; Wang Z; Chen P; Wang Q; Lu J; Wang Y; Li P; Wang J; Lu X; Yuan J
    Medicine (Baltimore); 2015 Dec; 94(49):e2222. PubMed ID: 26656362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.
    Ravaud A; Motzer RJ; Pandha HS; George DJ; Pantuck AJ; Patel A; Chang YH; Escudier B; Donskov F; Magheli A; Carteni G; Laguerre B; Tomczak P; Breza J; Gerletti P; Lechuga M; Lin X; Martini JF; Ramaswamy K; Casey M; Staehler M; Patard JJ;
    N Engl J Med; 2016 Dec; 375(23):2246-2254. PubMed ID: 27718781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter Study.
    Kim SH; Kim S; Nam BH; Lee SE; Kim CS; Seo IY; Kim TN; Hong SH; Kwon TG; Seo SI; Joo KJ; Song K; Kwak C; Chung J
    PLoS One; 2015; 10(8):e0135165. PubMed ID: 26308612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world use of sorafenib for advanced renal cell carcinoma patients with cardiovascular disease: nationwide survey in Japan.
    Inamoto T; Azuma H; Tatsugami K; Oya M; Adachi M; Okayama Y; Sunaya T; Akaza H
    Expert Rev Anticancer Ther; 2020 Jul; 20(7):615-623. PubMed ID: 32441582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.
    Margulis V; Matin SF; Tannir N; Tamboli P; Swanson DA; Jonasch E; Wood CG
    J Urol; 2008 Jul; 180(1):94-8. PubMed ID: 18485389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial.
    Lee Z; Jegede OA; Haas NB; Pins MR; Messing EM; Manola J; Wood CG; Kane CJ; Jewett MAS; Flaherty KT; Dutcher JP; DiPaola RS; Uzzo RG
    J Urol; 2020 Apr; 203(4):684-689. PubMed ID: 31596672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
    Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
    Sheng X; Chi Z; Cui C; Si L; Li S; Tang B; Mao L; Lian B; Wang X; Yan X; Guo J
    Oncotarget; 2016 May; 7(19):27044-54. PubMed ID: 26894858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.